This guidance provides recommendations for how requestors can comply with the requirements described in the Proposed Administrative Order titled Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs.
Similar Posts
FDA Clinical Trials Training Modules
This training represents regulatory intelligence that sets global standards for clinical research. The content reflects current FDA thinking, emerging guidance, and real-world regulatory experience, providing participants with the most reliable and up-to-date information available.Search for Regulatory References | Drugs
Find information on drug development, applications, submissions, manufacturing & quality, safety, labeling and moreSystem Correction: IMPRIS Imaging Inc Issues Correction for IMRIS Neuro III-SV
IMPRIS corrects IMRIS Neuro III-SV models due to the potential of ice blockage in the helium venting pipeFDA Adverse Event Reporting System (FAERS) Electronic Submissions
This page provides drug and nonvaccine biological product manufacturers, distributors, packers, outsourcing facilities, and other interested parties with information about FDA Adverse Event Reporting System (FAERS) electronic submissions and instructions on how to electronically submit postmarketingConsumers Supply Distributing, LLC Recalls Country Vet Biscuits for Dogs Due to Possible Salmonella Health Risk
Consumers Supply Distributing, LLC of Sioux City, Iowa is recalling 4 lb. bags of Country Vet Biscuits – Original Meaty Flavor and 4 lb. bags of Heartland Harvest Dog Biscuits – Meaty Flavor with Chicken because they have the potential to be contaminated with Salmonella. Salmonella can affect animalFDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel
